News | April 22, 2023
LTS acquires Sorrel wearable injection device business
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Bourgoin early development hub broadens offerings for oral solid dose formulations
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Subscribe To Our Newsletter & Stay Updated
